BioSpace News Archive

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces further details of the positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118).

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN) today announced that new preclinical data from a transgenic mouse model evaluating TERN-601, the Company’s novel oral GLP-1R agonist, were highlighted in a poster presentation at the American Diabetes Association’s 83rd Annual Scientific Sessions, which took place from June 23-26, 2023 in San Diego.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, June 27, 2023, at 8:00 a.m. (ET) to provide top-line results from the Phase 2 clinical trial of ADX‑629 in patients with chronic cough.

Instil Bio, Inc. (“Instil”) (NASDAQ: TIL) today reported an oral presentation at the British Society for Gene and Cell Therapy Annual Conference, demonstrating that its proprietary CoStimulatory Antigen Receptor (CoStAR) platform enhances activity of TILs against autologous tumor.

Today, findings from the COORDINATE-Diabetes trial demonstrated that multi-disciplinary care between cardiologists, diabetes specialists and other team members can significantly increase the prescriptions of evidence-based therapies to help treat patients with both type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD), commonly known as heart disease.

Sosei Group Corporation notes the decision by its partner Pfizer to prioritize the development of clinical-stage GLP-1 receptor agonist candidate danuglipron for the treatment of diabetes and obesity and as a result has discontinued the development of lotiglipron – see Pfizer press announcement here.

ATCOR Medical today announces it has entered into a partnership agreement with Datacubed Health, a leading eClinical technology company, advancing access to healthcare for everyone, everywhere.

AptarGroup, Inc., announced with great sadness that Ervin “Erv” J. LeCoque, the first Chief Executive Officer and Chairman of the Board when Aptar became a publicly traded company, has passed away.

Upsher-Smith Laboratories, LLC announced that it has entered into a definitive agreement under which New Jersey-based Tonix Pharmaceuticals Holding Corp. and its wholly owned subsidiary Tonix Medicines, Inc. have acquired Zembrace® SymTouch® 3 mg and Tosymra® 10 mg.

MoonLake Immunotherapeutics announced that it has commenced an underwritten public offering of $250 million of its Class A ordinary shares and, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase Class A ordinary shares.